Oramed Net Income Per E B T from 2010 to 2024

ORMP Stock  USD 2.52  0.06  2.44%   
Oramed Pharmaceuticals Net Income Per E B T yearly trend continues to be relatively stable with very little volatility. Net Income Per E B T is likely to drop to 0.70. During the period from 2010 to 2024, Oramed Pharmaceuticals Net Income Per E B T destribution of quarterly values had r-value of  0.37 from its regression line and median of  1.00. View All Fundamentals
 
Net Income Per E B T  
First Reported
2010-12-31
Previous Quarter
1.08588836
Current Value
0.7
Quarterly Volatility
0.53940615
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Oramed Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oramed Pharmaceuticals' main balance sheet or income statement drivers, such as Selling General Administrative of 8.8 M, Other Operating Expenses of 10.7 M or Research Development of 7.6 M, as well as many indicators such as Price To Sales Ratio of 74.82, Dividend Yield of 0.0 or PTB Ratio of 0.6. Oramed financial statements analysis is a perfect complement when working with Oramed Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Oramed Pharmaceuticals Correlation against competitors.
To learn how to invest in Oramed Stock, please use our How to Invest in Oramed Pharmaceuticals guide.

Latest Oramed Pharmaceuticals' Net Income Per E B T Growth Pattern

Below is the plot of the Net Income Per E B T of Oramed Pharmaceuticals over the last few years. It is Oramed Pharmaceuticals' Net Income Per E B T historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oramed Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Income Per E B T10 Years Trend
Slightly volatile
   Net Income Per E B T   
       Timeline  

Oramed Net Income Per E B T Regression Statistics

Arithmetic Mean0.86
Coefficient Of Variation62.88
Mean Deviation0.28
Median1.00
Standard Deviation0.54
Sample Variance0.29
Range2.2008
R-Value0.37
Mean Square Error0.27
R-Squared0.14
Significance0.18
Slope0.04
Total Sum of Squares4.07

Oramed Net Income Per E B T History

2024 0.7
2023 1.09
2019 0.97
2017 1.02
2016 1.04
2015 1.14

About Oramed Pharmaceuticals Financial Statements

Oramed Pharmaceuticals shareholders use historical fundamental indicators, such as Net Income Per E B T, to determine how well the company is positioned to perform in the future. Although Oramed Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Oramed Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Oramed Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Net Income Per E B T 1.09  0.70 

Pair Trading with Oramed Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oramed Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oramed Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Oramed Stock

  0.36EWTX Edgewise TherapeuticsPairCorr
  0.35VRNA Verona Pharma PLCPairCorr
  0.34ELDN Eledon PharmaceuticalsPairCorr
  0.32ETON Eton Pharmaceuticals Potential GrowthPairCorr
The ability to find closely correlated positions to Oramed Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oramed Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oramed Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oramed Pharmaceuticals to buy it.
The correlation of Oramed Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oramed Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oramed Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oramed Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Oramed Stock Analysis

When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.